News
- Author:
- Zosia Chustecka
Publish date: May 31, 2022
The “approvals bring two first-line immunotherapy-based treatment options at once ... to newly diagnosed patients with unresectable advanced or met...
News
- Author:
- Zosia Chustecka
Publish date: March 1, 2022
Treatment option is the first for patients who have myelofibrosis with low platelet counts.
News
- Author:
- Zosia Chustecka
Publish date: March 1, 2022
Study results show that this treatment for refractory/relapsed multiple myeloma can provide deep, durable responses and long treatment-free interva...
News
- Author:
- Zosia Chustecka
Publish date: February 18, 2022
First-ever drug for hemolytic anemia has been approved by the Food and Drug Administration.
News
- Author:
- Zosia Chustecka
Publish date: February 7, 2022
The first drug to treat a rare anemia has been given the green light by the FDA.
News
- Author:
- Zosia Chustecka
Publish date: October 13, 2021
Abemaciclib had already been approved for use in the treatment of HR+, HER2– advanced or metastatic breast cancer.
News
- Author:
- Zosia Chustecka
Publish date: September 16, 2021
Pembrolizumab is for first-line locally advanced or metastatic urothelial carcinoma for patients not eligible for platinum-containing chemotherapy....
News
- Author:
- Zosia Chustecka
Publish date: July 15, 2021
Consumers should stop using these products and throw them away, the company said.
News
- Author:
- Zosia Chustecka
Publish date: June 1, 2021
The new drug, sotorasib (Lumakras), specifically targets the KRAS G12C mutation, which accounts for about 13% of ...
News
- Author:
- Zosia Chustecka
Publish date: April 27, 2021
Prescribers are recommended to monitor patients for edema or effusions, and to consider diagnostic imaging in pat...
News
- Author:
- Zosia Chustecka
Publish date: March 29, 2021
“The results of this trial represent a true turning point in the treatment of this disease.”
News
- Author:
- Zosia Chustecka
Publish date: February 16, 2021
The FDA has approved trilaciclib (Cosela), a first-in-class drug given before chemotherapy to protect against che...
News
- Author:
- Zosia Chustecka
Publish date: December 2, 2020
The diagnostic agent Gallium 68 PSMA-11 has been approved for institutional use only.
News
- Author:
- Zosia Chustecka
Publish date: November 30, 2020
Naxitamab has been approved for pediatric and adult patients with relapsed/refractory neuroblastoma.
News
- Author:
- Zosia Chustecka
Publish date: September 8, 2020
Pralsetinib (Gavreto) was granted accelerated approval to treat patients with RET-positive non–small cell lung ca...
